Dr Michelle Samuel (McGill University Health Centre, Canada) and colleagues evaluated the long-term effectiveness of catheter ablation in patients with AF-HF in reducing the incidence of all-cause mortality, HF hospitalisations, and major morbidities (i.e. stroke/TIA and major bleeding) [1]. A population-based administrative cohort of 87,676 AF-HF patients was created for this purpose . Patients who underwent catheter ablation (n=298) were matched 1:2 to controls (n=591) using risk-set sampling. Cases were matched on time in the cohort and frequency of hospitalisations.
After inverse probability of treatment weighting, the distribution of covariates was balanced between cases and controls with age 65.6 vs 61.6 years, women 24% vs 20%, CHA2DS2-Vasc score 3.2 vs 2.9, and catheter ablation vs non-catheter ablation, respectively (standardised mean differences was <0.1 for all). The median follow-up was 3.3 years. A total of 7.3% of catheter ablation patients died vs 24.6% of non-catheter ablation patients. After weighting and adjustment, catheter ablation was associated with a statistically significant reduction in the incidence of all-cause mortality (adjusted HR 0.5). No statistically significant difference was observed in the incidence of HF hospitalisations during follow-up (catheter ablation 22.5% vs non-catheter ablation 27.1%; adjusted HR 0.9). The incidence of stroke/TIA (1.7% vs 6.8%) and major bleeding (1.7% vs 4.9%) in patients who had catheter ablation compared with those who had not, were not statistically different.
1. Samuel M, et al. Catheter ablation is associated with reduced all-cause mortality in a real-world cohort of patients with atrial fibrillation and heart failure. FP Number P1024. ESC Congress 2019, 31 Aug-4 Sept, Paris, France.
Posted on
Previous Article
« Salt substitution programme successful in lowering blood pressure Next Article
Inclisiran offers substantial LDL-C reductions in ASCVD patients »
« Salt substitution programme successful in lowering blood pressure Next Article
Inclisiran offers substantial LDL-C reductions in ASCVD patients »
Related Articles
December 29, 2020
CABG grafting risk thresholds differ between men and women
© 2024 Medicom Medical Publishers. All rights reserved. Terms and Conditions | Privacy Policy
HEAD OFFICE
Laarderhoogtweg 25
1101 EB Amsterdam
The Netherlands
T: +31 85 4012 560
E: publishers@medicom-publishers.com